Wrzodziejące zapalenie jelita grubego: badanie fazy II leku SPYPBO-101 i SPY002
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Badania kliniczne prowadzone w ośrodku Sonomed Sp. z o.o. (Ul. Ks. Bp. Wladyslawa Bandurskiego 98/u12, Szczecin), które rekrutują lub wkrótce zaczną rekrutację. Dane pochodzą z rejestrów badań.
23 badania: 23 rekrutują.
Ośrodek niezweryfikowany
Sonomed Sp. z o.o.
Ul. Ks. Bp. Wladyslawa Bandurskiego 98/u12
Szczecin
Otwórz w Mapach Google · OpenStreetMap
Nie znaleźliśmy dokładnego adresu na mapie, dlatego pokazujemy miasto.
Ośrodek niezweryfikowany. Nazwa, adres i lista badań pochodzą z publicznych rejestrów badań klinicznych (CTIS, ClinicalTrials.gov). Ośrodek nie potwierdził tych danych z nami. Przed wizytą zadzwoń do nas, a nasz doradca sprawdzi aktualne informacje.
Mapa: © autorzy OpenStreetMap
Wpisz słowo, żeby przeszukać wszystkie 23 badania.
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed, moderate-to-severe Crohn’s disease: A 52-week…
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed moderate-to-severe ulcerative colitis: A 52-week…
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone Deficiency
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 17 listopada 2026.